Fda approves johnson & johnson's imaavytm (nipocalimab-aahu) a new treatment for myasthenia gravis (mg), offering hope for families

First and only fcrn blocker approved in anti-achr and anti-musk antibody positive adults and pediatric gmg patients aged 12 and older. first and only fcrn blocker approved in anti-achr and anti-musk antibody positive adults and pediatric gmg patients aged 12 and older.
MG Ratings Summary
MG Quant Ranking